NCCN 2024 Annual Conference

April 5, 2024 to April 7, 2024

The NCCN 2024 Annual Conference includes educational sessions that highlight significant updates and key issues for select NCCN Guidelines®, new and emerging therapies, controversies in oncology care, issues affecting oncology care, and strategies to address barriers to practice.

Target Audience

This educational program is designed to meet the educational needs of physicians/oncologists, nurse practitioners, nurses, PAs, pharmacists, and other health care professionals who manage patients with cancer.

Learning Objectives

The goal of NCCN continuing education is to change patient outcomes by improving the competence and performance of clinicians. The goal of the NCCN 2024 Annual Conference is to ensure that members of the interprofessional oncology care team, including physicians, nurse practitioners, nurses, PAs, pharmacists, and other relevant health care professionals, have the knowledge and skills necessary to:

  • Apply the current recommendations of oncology care and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) to optimize the management of patients with cancer.
  • Evaluate new, emerging, and novel therapeutic agents, treatment strategies, and clinical trials data and apply relevant findings into the management of patients with cancer.
  • Communicate with members of the interprofessional oncology care team to improve collaborative performance in the management of patients with cancer and the delivery of oncology care.

Learning objectives for individual conference sessions are viewable here.

Additional information
Supporters: 

Supported by educational grants from:

  • AstraZeneca
  • Coherus BioSciences
  • Dendreon Pharmaceuticals LLC.
  • Eisai
  • Exact Sciences
  • Genentech, a member of the Roche Group
  • GRAIL, LLC
  • GSK
  • Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Lilly
  • Menarini-Stemline
  • Novartis
  • Novocure
  • Olympus Corporation of the Americas
  • Sanofi
  • Sirtex
  • Taiho Oncology, Inc.

Supported by a grant from:

  • Pfizer Inc.

This project has been made possible in part by a grant from:

  • Varian Medical Systems, a Siemens Healthineers company/Global Medical Education Grant Program

Supported by independent educational grants from:

  • Daiichi Sankyo
  • Incyte Corporation
  • Merck & Co., Inc., Rahway, NJ, USA

Supported by independent medical education grants from:

  • Boehringer Ingelheim Pharmaceuticals, Inc.
  • Regeneron Pharmaceuticals, Inc.

Supported by a medical education grant from:

  • Karyopharm Therapeutics
Course summary
Available credit: 
  • 30.25 AAPA Category 1 CME credit
  • 30.25 AMA PRA Category 1 Credit™
  • 30.25 ANCC contact hours
    • 17.50 ANCC Pharmacology Contact Hours
  • 30.25 CCM clock hours
  • 30.25 Participation
Course opens: 
04/05/2024
Course expires: 
08/01/2024
Event starts: 
04/05/2024 - 8:00am EDT
Event ends: 
04/07/2024 - 12:35pm EDT
Cost:
$0.00

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Click here to download the faculty disclosures for this program.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
NCCN designates this live activity for a maximum of 30.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses
NCCN designates this educational activity for a maximum of 30.25 contact hours. This program offers up to 17.5 pharmacotherapeutic contact hours for nurses. Eligible sessions are noted on the agenda with a double asterisk (**).

Pharmacists
NCCN designates this knowledge-based continuing education activity for 30.25 contact hours (3.025 CEUs) of continuing education credit. UAN: JA4008196-0000-24-019-L01-P

Physician Assistants
NCCN has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 30.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Case Managers
This program has been pre-approved by The Commission for Case Manager Certification to provide continuing education credit to CCM® board certified case managers. The course is approved for 30.25 CE contact hours. Activity code: C00058945 Approval Number: 240001018

American Board of Internal Medicine Maintenance of Certification (MOC)


Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 30.25 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Pathology Continuing Certification (CC)


This activity has been registered to offer credit in the American Board of Pathology’s (ABPath) Continuing Certification program. Participants may earn up to 30.25 Lifelong Learning (Part II) credits.

Aggregated participant data will be shared with the commercial supporters of this activity.

American Board of Surgery Continuous Certification (CC)

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

American Board of Medical Specialties Maintenance of Certification (MOC)
Through the American Board of Medical Specialties (“ABMS”) ongoing commitment to increase access to practice relevant Continuing Certification Activities through the ABMS Continuing Certification Directory, the NCCN 2024 Annual Conference has met the requirements as a Lifelong Learning CME Activity (apply toward general CME requirement) for the following ABMS Member Boards: 

ABMS Lifelong Learning CME Activity
Colon and Rectal Surgery
Medical Genetics and Genomics
Radiology

Available Credit

  • 30.25 AAPA Category 1 CME credit
  • 30.25 AMA PRA Category 1 Credit™
  • 30.25 ANCC contact hours
    • 17.50 ANCC Pharmacology Contact Hours
  • 30.25 CCM clock hours
  • 30.25 Participation

Price

Cost:
$0.00
Please login or register to take this course.

Click the Take Course button to start the credit claiming process. You must be logged in with the email address used for registration.

CE/MOC credit should be claimed for the conference as a whole, not session by session. You may claim credit for the conference only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings until eary June.) 

Pharmacists: you must complete all requirements for credit by Tuesday, May 28, 2024.

Tracking Your Session Attendance: Click here to help keep track of your session attendance. The enclosed worksheets are for your reference only and should not be returned to NCCN staff. Completion of these worksheets is not required to claim continuing education credit.

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection
  • Adobe Reader or other PDF reader software for certificate viewing/printing